Davies is new non-executive director on TrakCel board
TRAKCEL, the software developer for cell and gene therapy supply chain tracking and orchestration, has appointed a new non-executive director as it strives to triple revenues by year end.
Dr Anthony Davies, from Dark Horse Consulting, joins the board of the company, which has its headquarters in Cardiff, to strengthen its position as the leading provider of needle-to-needle cell orchestration technology to support the development and commercialisation of regenerative therapies.
After training as a biochemist, chemical engineer and molecular biologist, Dr. Davies has worked in the cell and gene therapy field for over 20 years.
He brings with him an extensive track record in manufacturing, operational management and commercial development. Most recently, he was chief technology officer for Capricor Inc and vicepresident of product development for Geron Corporation’s cell therapy programs.
He received an MA in biochemistry from the University of Cambridge and a PhD in chemical engineering from the University of Birmingham.
At TrakCel, Dr Davies will use his considerable experience to provide regulatory consultancy and advice on the company’s processes and governance to contribute to the firm’s growth plans. His regulatory expertise adds to the current leadership’s strong background in clinical research, supply chain, cell therapy development and manufacture, and information technology.
Recently, TrakCel announced it had opened its second US office in New Jersey to achieve its growth targets, which include tripling its client base and revenue by the end of 2017.
On his appointment, Dr Davies said: “TrakCel has made several significant appointments recently and I’m thrilled to join this growing and talented team at a crucial time in the firm’s development.”